NCT06194201

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

A Multi-centre, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis

Conditions

• Patients With Candidemia and/or Invasive Candidiasis

Interventions

Type	Name	Description
DRUG	HRS9432	Dosing frequency: intravenously once week
DRUG	Caspofungin Acetate for Injection	Dosing frequency: D1 70mg，followed by 50mg intravenously once daily

Timeline

• Start date: 2024-04-27
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2024-01-08
• Last updated: 2024-11-18

Locations

1 site across 1 country: China